A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
Completed · Phase 1 · NCT06397872
Conditions: Renal Impairment
At a glance
- Research payments reported, 2025
- $50,899
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 28
About the trial
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Tested
- 100 mg Resmetirom Tablet (drug)
- Dates
- Started 2024-03-06; completion 2024-12-31
- Results posted
- Not yet
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of resmetirom and its major metabolite (MGL-3623) following oral administration of 100 mg resmetirom (QD x 6 days) in subjects with severe renal impairment (RI) compared to healthy matched control subjects with normal renal function.
From ClinicalTrials.gov, last updated 2025-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Madrigal Pharmaceuticals reported $50,899 in research payments for this study in 2025 (2 payments).
Products named: Rezdiffra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Thomas C. Marbury, M.D. Nephrology (Kidney) · Orlando, FL
- April R. Kennedy, M.D. Nephrology (Kidney) · Chicago, IL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Research By Design $49,149
- Orlando Clinical Research Center $1,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.